Cas:149719-06-2 3-piperidin-1-ylpropyl 4-amino-5-chloro-2-methoxybenzoate,hydrochloride manufacturer & supplier

Chemical Name:3-piperidin-1-ylpropyl 4-amino-5-chloro-2-methoxybenzoate,hydrochloride

CAS.NO:149719-06-2

Synonyms:Trequinsin hydrochloride

Molecular Formula:C₁₆H₂₄Cl₂N₂O₃

Molecular Weight:363.27900

HS Code:2933399090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:486.5ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:64.79000

Exact Mass:362.11600

LogP:4.28470

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Trequinsin hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Trequinsin hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Trequinsin hydrochloride Use and application,Trequinsin hydrochloride technical grade,usp/ep/jp grade.

Related News: For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.” 3-piperidin-1-ylpropyl 4-amino-5-chloro-2-methoxybenzoate,hydrochloride manufacturer Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees. 3-piperidin-1-ylpropyl 4-amino-5-chloro-2-methoxybenzoate,hydrochloride supplier Speaking to Sky News, Raab said he could not confirm the ��precise number�� of those arriving into the UK on Sunday. 3-piperidin-1-ylpropyl 4-amino-5-chloro-2-methoxybenzoate,hydrochloride vendor Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 3-piperidin-1-ylpropyl 4-amino-5-chloro-2-methoxybenzoate,hydrochloride factory For Jefferies, this “has not been demonstrated to convincingly reduce Abeta plaque burden, in our view.” The firm forecasts $3 billion in global sales for gantenerumab, but at a striking 0%, “so probability so no contribution.”